Yale University

Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.

TitleLong-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.
Publication TypeJournal Article
Year of Publication2008
AuthorsFiellin, David A., Brent A. Moore, Lynn E. Sullivan, William C. Becker, Michael V. Pantalon, Marek C. Chawarski, Declan T. Barry, Patrick G. O'Connor, and Richard S. Schottenfeld
JournalThe American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions
Date Published2008 Mar-Apr
KeywordsAdult, Buprenorphine, Combined Modality Therapy, Counseling, Cross-Sectional Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Heroin Dependence, Humans, Long-Term Care, Male, Middle Aged, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Patient Dropouts, Primary Health Care, Substance Abuse Detection, Treatment Outcome
AbstractTo examine long-term outcomes with primary care office-based buprenorphine/naloxone treatment, we followed 53 opioid-dependent patients who had already demonstrated six months of documented clinical stability for 2-5 years. Primary outcomes were retention, illicit drug use, dose, satisfaction, serum transaminases, and adverse events. Thirty-eight percent of enrolled subjects were retained for two years. Ninety-one percent of urine samples had no evidence of opioid use, and patient satisfaction was high. Serum transaminases remained stable from baseline. No serious adverse events related to treatment occurred. We conclude that select opioid-dependent patients exhibit moderate levels of retention in primary care office-based treatment.
Alternate JournalAm J Addict

External Links